Mylan Says $107M Verdict Should Stand In Generic Paxil Fight
Mylan Inc. urged the Third Circuit on Monday to uphold a $106.7 million jury verdict against GlaxoSmithKline PLC, saying there was sufficient evidence for its claims that GSK breached an exclusivity...To view the full article, register now.
Already a subscriber? Click here to view full article